Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735366 | 0.82 | CYP1A2 (0.56) | CYP1A2TDP1HTR1AHTTHSD11B1 | |
| SCHEMBL735365 | 0.82 | CYP1A2 (0.56) | CYP1A2TDP1HTR1AHTTHSD11B1 | |
| SCHEMBL6246335 | 0.80 | CYP1A2 (0.54) | CYP1A2TDP1HTR1AHTTHSD11B1 | |
| SCHEMBL967286 | 0.79 | — | — | |
| SCHEMBL965723 | 0.77 | ALDH1A1 (0.48) | TDP1HTTPOLB | |
| SCHEMBL2197708 | 0.73 | CA2 (0.48) | HSD11B1POLBEPHX2 | |
| SCHEMBL967471 | 0.73 | SMN1; SMN2 (0.54) | HTTMAPT | |
| SCHEMBL5470776 | 0.73 | CYP1A2 (0.65) | CYP1A2TDP1HTR1AHTTHSD11B1 | |
| SCHEMBL1965092 | 0.70 | CYP1A2 (0.62) | CYP1A2TDP1HTR1AHTTHSD11B1 | |
| Hydrochloric Acid SCHEMBL15209250 | 0.70 | CYP1A2 (0.62) | CYP1A2TDP1HTR1AHTTHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | claimed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | claimed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | claimed |
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058315-A1 | Integrase inhibitors | TYMP, DNTT, PAICS | CYP1A2 1583/4885TDP1 28/4885HTR1A 3706/4885 |
| US-20090306054-A1 | INTEGRASE INHIBITORS | TYMP, POLR2E, CCNI | CYP1A2 757/4885TDP1 63/4885HTR1A 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.